drugset / Trial / NCT07430917

Safety and Efficacy of J147 in Acute Ischemic Stroke

NCT07430917 ↗

Phase 2 Not yet recruiting 196 enrolled Abrexa Pharmaceuticals, Inc. IQVIA RDS Inc. · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clear the blood clot to those who don't receive J147. Participants will be asked to undergo a series of three to four magnetic resonance imaging (MRI) brain scans, and blood samples will be collected at several time points. Participants will also be evaluated to measure several aspects of brain function.

Timeline

Start
2026-04-20
Primary completion
2028-03-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject J147 Small molecule 1.6 mg/kg Intravenous
Subject J147 Small molecule 2.5 mg/kg Intravenous

Indications